Cutaneous late phase reaction in adult atopic dermatitis patients with high serum IgE antibody to Dermatophagoides farinae: correlation with IL-5 production by allergen-stimulated peripheral blood mononuclear cells
“…There were decreases in eosinophil infiltration, the expression of Th2 cytokine mRNA and the IgE response only when the mice were treated with CpG plus OVA; these effects were not demonstrable in a group treated with CpG ODN alone. These observations clearly show that CpG ODN (plus OVA) are capable of redirecting an immune response to specific Ag in animals with established skin eosinophilic inflammation showing diffuse edematous erythema [3].…”
Section: Discussionmentioning
confidence: 66%
“…It is noteworthy that the cutaneous late phase reaction (LPR), which appears to be clinically associated with diffuse edematous erythema, often occurs in patients with severe AD [3]. To develop a new therapeutic modality for AD showing the immunopathological features of LPR, the development of a model of cutaneous LPR is required.…”
The number of patients with severe atopic dermatitis (AD) has been on the rise recently. We are therefore urgently in need of a treatment that can suppress Th2 cell-mediated responses in an Ag-specific fashion. Oligodeoxynucleotides (ODN)containing CpG motifs (CpG ODN) have been highlighted as immunomodulators that reduce Th2-mediated responses. To determine the effect of CpG ODN on Th2-mediated skin inflammation, we first developed a reproducible murine model of protein Ag-induced eosinophilic inflammation that is accompanied by epidermal acanthosis and increased serum IgE levels as seen in AD. In this model we found that treatment with CpG ODN during epicutaneous sensitization in previously i.p.-primed mice prevented the development of Th2-mediated responses. Furthermore, to evaluate the therapeutic effect of CpG ODN on established eosinophilic inflammation, mice were treated with a course of the immunotherapy at a skin site remote from the area of Ag application prior to the second 1-wk epicutaneous exposure to Ag. Therapeutic treatment with CpG ODN plus Ag, but not that with CpG ODN alone, could reverse the established eosinophilic inflammation. The presented results provide strong evidence for the feasibility of a novel Ag-specific immunomodulator to treat cutaneous eosinophilic inflammation such as that characteristically found in patients with severe AD.
“…There were decreases in eosinophil infiltration, the expression of Th2 cytokine mRNA and the IgE response only when the mice were treated with CpG plus OVA; these effects were not demonstrable in a group treated with CpG ODN alone. These observations clearly show that CpG ODN (plus OVA) are capable of redirecting an immune response to specific Ag in animals with established skin eosinophilic inflammation showing diffuse edematous erythema [3].…”
Section: Discussionmentioning
confidence: 66%
“…It is noteworthy that the cutaneous late phase reaction (LPR), which appears to be clinically associated with diffuse edematous erythema, often occurs in patients with severe AD [3]. To develop a new therapeutic modality for AD showing the immunopathological features of LPR, the development of a model of cutaneous LPR is required.…”
The number of patients with severe atopic dermatitis (AD) has been on the rise recently. We are therefore urgently in need of a treatment that can suppress Th2 cell-mediated responses in an Ag-specific fashion. Oligodeoxynucleotides (ODN)containing CpG motifs (CpG ODN) have been highlighted as immunomodulators that reduce Th2-mediated responses. To determine the effect of CpG ODN on Th2-mediated skin inflammation, we first developed a reproducible murine model of protein Ag-induced eosinophilic inflammation that is accompanied by epidermal acanthosis and increased serum IgE levels as seen in AD. In this model we found that treatment with CpG ODN during epicutaneous sensitization in previously i.p.-primed mice prevented the development of Th2-mediated responses. Furthermore, to evaluate the therapeutic effect of CpG ODN on established eosinophilic inflammation, mice were treated with a course of the immunotherapy at a skin site remote from the area of Ag application prior to the second 1-wk epicutaneous exposure to Ag. Therapeutic treatment with CpG ODN plus Ag, but not that with CpG ODN alone, could reverse the established eosinophilic inflammation. The presented results provide strong evidence for the feasibility of a novel Ag-specific immunomodulator to treat cutaneous eosinophilic inflammation such as that characteristically found in patients with severe AD.
“…However, we were surprised to find that many patients had a late‐phase response to gliadin. Late‐phase response occurring 6 to 12 hours after skin prick testing is described in the literature, in particular in atopic disease subjects, and is blocked by glucocorticosteroids 8, 9. It is mainly caused by other immune mediators (slow reacting substances such as interleukin 5) rather than histamine (immediately reacting substance), which are in any case released by IgE‐dependent mast cell degranulation 10.…”
We share the response to the letter from Zhong and Yang by providing an empirical finding as follows: In a previous study, we demonstrated that the effect of diabetes on hepatocelluar carcinoma (HCC) is manifested in patients who are hepatitis C virus (HCV) negative but not in those who are HCV positive.
“…Mites, Myobia musculi, inhabit mice as prasites (SLC Inc., Hamamatsu, Japan) to possibly lead to AD-like lesions. To date, in most human AD patients, Dermatophagoides mites [19] have been shown to cause AD. In conventional NC mice, over-production of Th2 cytokines such as IL-4 and elevated serum IgE antibodies [18] beyond the age of 8 weeks were evident.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.